头孢孟多在肾衰竭患者中的药代动力学。
Pharmacokinetics of cefamandole in patients with renal failure.
作者信息
Meyers B R, Hirschman S Z
出版信息
Antimicrob Agents Chemother. 1977 Feb;11(2):248-50. doi: 10.1128/AAC.11.2.248.
Abstract
The pharmacokinetics of cefamandole were studied in four patients with stable renal failure, two patients undergoing peritoneal dialysis, and four patients undergoing hemodialysis. Peak concentrations of cefamandole in serum were achieved 1 to 2 h after intramuscular injection in the patients with stable renal impairment, and the concentrations declined slowly, with half-life values of 12.3 to 18 h. Cefamandole was removed only very slowly by peritoneal dialysis. Hemodialysis was more efficient in removing cefamandole, with serum half-life values ranging from 3.8 to 7.9 h. The mean apparent volume of distribution of cefamandole in these 10 patients was 21.92 liters, or 31% of the body weight.
摘要
对4例稳定型肾衰竭患者、2例接受腹膜透析的患者和4例接受血液透析的患者进行了头孢孟多的药代动力学研究。在稳定型肾功能损害患者中，肌内注射后1至2小时血清中头孢孟多达到峰值浓度，且浓度下降缓慢，半衰期值为12.3至18小时。腹膜透析清除头孢孟多的速度非常缓慢。血液透析清除头孢孟多的效率更高，血清半衰期值为3.8至7.9小时。这10例患者中头孢孟多的平均表观分布容积为21.92升，占体重的31%。
相似文献
1
Pharmacokinetics of cefamandole in patients with renal failure.头孢孟多在肾衰竭患者中的药代动力学。
Antimicrob Agents Chemother. 1977 Feb;11(2):248-50. doi: 10.1128/AAC.11.2.248.
2
Pharmacokinetics of cefamandole in patients undergoing hemodialysis and peritoneal dialysis.头孢孟多在接受血液透析和腹膜透析患者中的药代动力学。
Antimicrob Agents Chemother. 1976 Sep;10(3):457-61. doi: 10.1128/AAC.10.3.457.
3
Pharmacokinetics of cefamandole in the presence of renal failure in patients undergoing hemodialysis.头孢孟多在接受血液透析的肾衰竭患者中的药代动力学。
Antimicrob Agents Chemother. 1976 Oct;10(4):623-5. doi: 10.1128/AAC.10.4.623.
4
Pharmacokinetics of cefamandole in patients with renal impairment.头孢孟多在肾功能损害患者中的药代动力学。
Antimicrob Agents Chemother. 1979 Feb;15(2):161-4. doi: 10.1128/AAC.15.2.161.
5
Cefamandole kinetics in uremic patients undergoing hemodialysis.头孢孟多在接受血液透析的尿毒症患者中的动力学。
Clin Pharmacol Ther. 1979 Nov;26(5):592-9. doi: 10.1002/cpt1979265592.
6
Pharmacokinetics of ceforanide in patients with end stage renal disease on hemodialysis.头孢雷特在接受血液透析的终末期肾病患者中的药代动力学。
Antimicrob Agents Chemother. 1980 Feb;17(2):251-3. doi: 10.1128/AAC.17.2.251.
7
The pharmacology of cefamandole in patients with reduced renal function.头孢孟多在肾功能减退患者中的药理学。
Scand J Infect Dis Suppl. 1980;suppl 25:45-8.
8
Pharmacokinetics of cefamandole in patients undergoing hemodialysis.头孢孟多在接受血液透析患者中的药代动力学。
Int J Clin Pharmacol Biopharm. 1979 Sep;17(9):416-20.
9
Disposition kinetics of cefamandole during continuous ambulatory peritoneal dialysis.头孢孟多在持续非卧床腹膜透析期间的处置动力学
Antimicrob Agents Chemother. 1986 Apr;29(4):649-53. doi: 10.1128/AAC.29.4.649.
10
Comparative pharmacokinetics of cefamandole, cephapirin, and cephalothin in healthy subjects and effect of repeated dosing.头孢孟多、头孢匹林和头孢噻吩在健康受试者中的比较药代动力学及重复给药的影响。
Antimicrob Agents Chemother. 1976 Sep;10(3):421-5. doi: 10.1128/AAC.10.3.421.
引用本文的文献
1
Drug therapy in patients undergoing peritoneal dialysis. Clinical pharmacokinetic considerations.接受腹膜透析患者的药物治疗。临床药代动力学考量
Clin Pharmacokinet. 1985 Sep-Oct;10(5):404-25. doi: 10.2165/00003088-198510050-00003.
2
Disposition kinetics of cefamandole during continuous ambulatory peritoneal dialysis.头孢孟多在持续非卧床腹膜透析期间的处置动力学
Antimicrob Agents Chemother. 1986 Apr;29(4):649-53. doi: 10.1128/AAC.29.4.649.
3
Clinical pharmacokinetics of antibiotics in patients with impaired renal function.肾功能受损患者抗生素的临床药代动力学
Clin Pharmacokinet. 1992 Mar;22(3):169-210. doi: 10.2165/00003088-199222030-00002.
4
Pharmacokinetics of cefamandole in patients with renal impairment.头孢孟多在肾功能损害患者中的药代动力学。
Antimicrob Agents Chemother. 1979 Feb;15(2):161-4. doi: 10.1128/AAC.15.2.161.
本文引用的文献
1
Excretion of cephaloridine and cephalothin in patients with renal impairment.肾功能损害患者中头孢菌素I和头孢噻吩的排泄情况。
N Engl J Med. 1966 Mar 24;274(12):654-6. doi: 10.1056/NEJM196603242741205.
2
Cefamandole, a cephalosporin antibiotic with an unusually wide spectrum of activity.头孢孟多，一种具有异常广泛活性谱的头孢菌素抗生素。
Antimicrob Agents Chemother. 1974 Aug;6(2):177-82. doi: 10.1128/AAC.6.2.177.
3
Cephalexin in patients with renal disease.
N Engl J Med. 1970 Oct 1;283(14):720-3. doi: 10.1056/NEJM197010012831402.
4
Cephalothin and cephaloridine: comparative pharmacodynamics in chronic uremia.
Am J Med Sci. 1969 Feb;257(2):116-24.
5
Antibacterial activity of cefamandole, a new cephalosporin antibiotic, compared with that of cephaloridine, cephalothin, and cephalexin.新型头孢菌素抗生素头孢孟多与头孢噻啶、头孢噻吩和头孢氨苄的抗菌活性比较。
Antimicrob Agents Chemother. 1973 Jun;3(6):657-61. doi: 10.1128/AAC.3.6.657.
6
Effect of hemodialysis and renal failure on serum and urine concentrations of cephapirin sodium.血液透析和肾衰竭对头孢匹林钠血清及尿液浓度的影响。
Antimicrob Agents Chemother. 1972 Feb;1(2):90-3. doi: 10.1128/AAC.1.2.90.
7
Blood and urine levels of cephalexin in patients with impaired renal function.
Med J Aust. 1972 Dec 2;2(23):1282-4. doi: 10.5694/j.1326-5377.1972.tb47583.x.
8
Pharmacological studies with cefamandole in human volunteers.头孢孟多在人体志愿者中的药理学研究。
Antimicrob Agents Chemother. 1976 Jan;9(1):140-4. doi: 10.1128/AAC.9.1.140.
9
Drug therapy. Clinical Pharmacokinetics (first of two parts).药物治疗。临床药代动力学（两部分中的第一部分）。
N Engl J Med. 1975 Oct 2;293(14):702-5. doi: 10.1056/NEJM197510022931406.
10
Cefamandole: antimicrobial activity in vitro of a new cephalosporin.头孢孟多：一种新型头孢菌素的体外抗菌活性
Antimicrob Agents Chemother. 1975 Dec;8(6):737-41. doi: 10.1128/AAC.8.6.737.
Zotero 插件